SANUWAVE Health, Inc. (SNWV) AI Stock Analysis
SNWV AI stock analysis summary
AI ResearchSANUWAVE Health, Inc. (NASDAQ: SNWV) is a medical device company focused on regenerative medicine and wound care technologies. Trailing twelve-month revenue reached $44.0M, but quarterly revenue contracted by 3.1% year-over-year in the quarter ended June 30, 2026. The stock has experienced sharp volatility, dropping 85.8% over the past year.
- Market cap
- $42.7M
- Revenue (TTM)
- $44.0M
- P/E
- 20.7x fwd 18.2x
- 1Y return
- -85.8% S&P 500 16.8%
- Avg. target
- $40.00 706.5% vs last close
Bull case
- Revenue expanded from $13.0M in FY2021 to $44.1M in FY2025, driving a 5-year revenue CAGR of 61.1%.
- Gross margin improved to 77.1% in FY2025, up from 61.7% reported in FY2021.
- Analyst estimates for the next fiscal year project revenue growth of 25.6% to $64.5M and an EPS of $0.37.
Bear case
- Quarterly revenue fell 3.1% year-over-year in the quarter ended June 30, 2026, with earnings declining 99.6%.
- Balance sheet leverage remains elevated, with total debt of $20.7M and a debt-to-equity ratio of 7.43 as of June 30, 2026.
- Shareholder dilution has been substantial, as the 5-year share count increased by 522.3%.
What SANUWAVE Health does
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets the UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds. Founded in 2004, the business is headquartered in Eden Prairie, Minnesota.
Growth and profitability
SANUWAVE delivered a 5-year revenue CAGR of 61.1% from FY2020 to FY2025. Annual revenue rose from $13.0M in FY2021 to $44.1M in FY2025, supported by 35.0% top-line growth in FY2025. Gross margin expanded to 77.1% in FY2025 from 61.7% in FY2021, while operating margin turned positive at 11.2%. The company reported net income of $11.8M in FY2025 after posting a net loss of $31.4M in FY2024. However, performance slowed in the latest quarter ended June 30, 2026, with quarterly revenue declining 3.1% year-over-year and quarterly earnings contracting 99.6%.
Balance sheet and cash flow
As of June 30, 2026, SANUWAVE held $9.4M in cash and short-term investments against total debt of $20.7M, resulting in net debt of $11.3M. Total assets stood at $36.6M, while shareholders' equity was $2.8M, reflecting a debt-to-equity ratio of 7.43 and a current ratio of 1.28. In FY2025, operating cash flow was $3.9M and free cash flow was $1.9M after capital expenditures of $1.9M. The company's 5-year share count increased by 522.3%.
Valuation and performance
SNWV closed at $4.96 on October 16, 2026, representing a market cap of $42.7M and an enterprise value of $51.2M. The stock trades at a trailing P/E of 20.7x and a forward P/E of 18.2x, compared to the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its enterprise value-to-revenue multiple is 1.2x, while its EV-to-EBITDA stands at 2.5x versus 12.0x for its peer group. Over the past year, SNWV fell 85.8%, underperforming the SPY return of 16.8%.
What analysts expect
Analysts have a mean price target of $40.00, compared to the last close of $4.96. For the current fiscal year ending December 31, 2026, the EPS estimate is -$0.08. Looking ahead to next fiscal year, 1 analyst projects revenue of $64.5M, representing 25.6% growth, and an EPS of $0.37. The company has beaten EPS estimates in 1 of the last 4 quarters, and the next earnings date is November 6, 2026.
Key risks and what to watch
- Operating margin turned negative to -2.9% on a trailing twelve-month basis, below the peer group median of 14.0%.
- Net debt stood at $11.3M on June 30, 2026, supported by $9.4M in cash and short-term investments.
- The stock has experienced extreme downside volatility, falling 83.4% year-to-date and trading 66.3% below its 200-day average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this SNWV AI stock analysis
This page is an AI-written research summary of SANUWAVE Health, Inc. (SNWV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: SNWV income statement, SNWV balance sheet, SNWV key metrics, SNWV analyst forecast, SNWV chart. See the SNWV stock overview for the latest quote and news.
SNWV AI stock analysis FAQ
What products does SANUWAVE Health commercialize?
SANUWAVE focuses on regenerative medicines using noninvasive ultrasound or shockwaves. Its primary commercial product is the UltraMist system, a medical device that uses non-thermal ultrasound and fluid mist to treat acute and chronic wounds.
What is SANUWAVE's current debt position?
As of June 30, 2026, SANUWAVE had $20.7M in total debt and $9.4M in cash and short-term investments, resulting in net debt of $11.3M. Its debt-to-equity ratio was 7.43.
What are analysts forecasting for SANUWAVE?
For the next fiscal year, 1 analyst forecasts revenue of $64.5M and an EPS of $0.37. The consensus price target is $40.00, compared to the recent close of $4.96.
Does SANUWAVE pay a dividend?
No, SANUWAVE does not pay a dividend.